contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


interim-report-second-quarter-april-1-june-30-2023-kancera-ab-publ-orgno-556806-8851

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Novakand Pharma is a pharmaceutical company. The company develops drugs that counteract damage caused by acute and chronic inflammation. The products are mainly developed to counteract hyperinflammation in various disease states and thereby protect vital organs, for example in connection with heart attacks and severe viral infections. Novakand Pharma is planning two clinical phase II studies, in COVID-19 and in heart patients. The company conducts research and development at Karolinska Institutet Science Park in Stockholm.

Novakand Pharma

The period in brief – financial summary for the second quarter Net sales amounted to SEK 0 million (SEK 0).R&D expenses amounted to SEK 16.5 million (SEK 14.7 million).Operating income for the...

<div class="mfn-body">The period in brief – financial summary for the second quarter <ul><li>Net sales amounted to SEK 0 million (SEK 0).</li><li>R&amp;D expenses amounted to SEK 16.5 million (SEK 14.7 million).</li><li>Operating income for the second quarter amounted to SEK -18.3 million (SEK -15.4 million). Income after financial items for the second quarter amounted to SEK -18.2 million (SEK -15.6 million).</li><li>Earnings per share, before and after dilution, for the second quarter amounted to SEK -0.22 (SEK-0.28).</li><li>Cash flow from operating activities for the second quarter amounted to SEK -14.8 million (SEK -14.4 million).</li><li>As of June 30, equity amounted to SEK 76.9 million (SEK 95.0 million) or SEK 0.94 (SEK 1.69) per share.</li><li>The equity/assets ratio on June 30 2023 was 84 percent (87 percent).</li><li>Cash and cash equivalents on June 30 2023 amounted to SEK 67.0 million (SEK 82.3 million).</li></ul>Significant events during the second quarter<ul><li>Kancera reported that the company has submitted the regulatory application to conduct a First-In- Human study of its fractalkine blocker KAND145.</li><li>Kancera reported that patient screening to the KANDOVA-study, a combined phase Ib/IIa study of the fractalkine blocker KAND567 in ovarian cancer patients, has been started.</li><li>Kancera reported the outcome of the exercise period for warrants of series TO6: approx.. 25 percent of outstanding warrants were utilized adding approximately SEK 5.9 million (before transaction costs) in cash to Kancera.</li><li>Kancera reported that Peter Selin is appointed as new Chief Executive Officer as of July 1 2023.</li><li>Kancera reported that the first patient in the KANDOVA study has been dosed with KAND567.</li></ul>Important events after the end of the period<ul><li>USPTO has granted a product patent for KAND567, manufactured according to Kancera’s patented manufacturing process, that enables Kancera to apply for data exclusivity and market protection for up to 7.5 year for the first indication approved in the United States.</li></ul> About Kancera AB (publ) Kancera is developing a new class of drugs for treatment of cancer and severe inflammatory diseases, that today are lacking effective treatments. Kancera’s main focus is to develop small molecule drug candidates based on the fractalkine axis. The fractalkine axis is a natural master regulator that with precision controls immune cells and cancer cells. The stock is traded on the Nasdaq First North Premier Growth Market. FNCA Sweden AB is the company's Certified Adviser.For further information: Peter Selin CEO, Kancera AB Phone: +46 (0)8-5012 60 80Visit Kancera’s web page: <a rel="noopener" href="https://www.kancera.com/en">https://www.kancera.com/en</a> This information is information that Kancera is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2023-08-18 08:30 CEST.</div><div class="mfn-footer mfn-regulatory mfn-regulatory-mar">This information is information that Kancera is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2023-08-18 08:30 CEST.</div><div class="mfn-footer mfn-attachment mfn-attachment-general">Attachments<hr><a rel="noopener" href="https://storage.mfn.se/52bc63f6-13c1-46a0-9dca-a89745af69c0/kancera-2023-q2-interim-report.pdf" class="mfn-primary">Kancera 2023 Q2 Interim Report</a></div>

Interim Report Second Quarter April 1 – June 30 2023 Kancera AB (publ.), org.no. 556806-8851

Talouden myyttejä murtamassa: Saksan teollisuus on menneen talven lumia

Federal Reserven korkopäätös: Riidankylväjät vauhdissa

On pakko painaa pitkää päivää? Ekonomisti fundeeraa

Nousuviikko takana, USA:n työllisyystaantuma ei edelleenkään luvuissa

Taloustieteen myyttejä murtamassa: Datakeskusinvestoinnit johtavat aina vain parempaan tekoälyyn